Jude Samulski, PhD Joins Gene Therapy Institute

The Gene Therapy Institute is proud to announce the appointment of R. Jude Samulski, PhD as an Adjunct Professor in the Department of Neurological Surgery. A globally recognized leader in the field of gene therapy, Dr. Samulski brings decades of groundbreaking experience in adeno-associate virus (AAV) vector development and translational research. 

Dr. Samulski was the first scientist to clone AAV and has since led pioneering efforts that have shaped the trajectory of gene therapy from concept to clinical reality. His scientific innovations have contributed to the development of numerous clinical trials and FDA-approved therapies, particularly for neurological and neuromuscular diseases. He is a prolific inventor and author, with over 250 peer-reviewed publications and dozens of patents related to gene delivery and vector design. 

As an adjunct professor, Dr. Samulski will collaborate with faculty across disciplines, advise on preclinical and translational research strategy, and support training efforts for students and early-career investigators. His appointment marks a significant step in the Institute's efforts to strengthen cross-disciplinary partnerships and expand impact on therapeutic innovation. 

For more information about the Gene Therapy Institute, visit https://gti.osu.edu.